Apimeds Pharmaceuticals US, Inc (APUS)
Oxford Ledge is still expanding full research coverage of APUS. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Apimeds operates two subsidiaries developing pharmaceutical therapies, primarily a bee venom-based treatment for osteoarthritis and multiple sclerosis. --- **Note on Financial Context:** Per SEC EDGAR FY2024 data, Apimeds reported net income of -$1.4M and operating cash flow of -$733.5K, reflecting its clinical stage development status.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-07-13
- 10-Q Quarterly financial report (unaudited) 2026-05-26
- 8-K Departure/election of directors or officers 2026-05-05
- 10-K Annual financial report with audited statements 2026-05-04
- 8-K Entry into material agreement; Departure/election of directors or officers; Other material event; Financial statements and exhibits 2026-05-04
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for APUS. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open APUS in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.